Scilex Holding Co. (SCLX)

May 1, 2025, 9:00 AM EDT - 13 days ago

Scilex Holding Company to Present Post-Hoc Analysis of the C.L.E.A.R. Trial on Clinical Meaningfulness of Safety and Efficacy of SP-102 for the Treatment of Lumbosacral Radicular Pain (LRP) at the 27th Annual Meeting of American Society of Interventional Pain Physicians (ASIPP), May 15-17, 2025 in Orlando, FL.

Apr 30, 2025, 1:46 PM EDT - 13 days ago

Scilex Holding Company Regains Compliance with NASDAQ Minimum Bid Price Rule

Apr 22, 2025, 9:00 AM EDT - 22 days ago

Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from April 11, 2025 to May 2, 2025

Apr 16, 2025, 2:12 PM EDT - 27 days ago

Scilex Holding Company Announces FDA Has Approved Our Request for the Orphan Drug Designation for Colchicine for the Treatment of Pericarditis

Apr 15, 2025, 9:00 AM EDT - 4 weeks ago

Scilex Holding Company Announces Approval of a New Drug Submission (NDS) from the Health Canada's Pharmaceutical Drugs Directorate, Bureau of Cardiology, Allergy and Neurological Sciences for ELYXYB®'s Acute Treatment of Migraine With or Without Aura in Canada

Apr 11, 2025, 9:00 AM EDT - 4 weeks ago

Scilex Holding Company Announces 1-for-35 Reverse Stock Split

Mar 26, 2025, 8:24 PM EDT - 6 weeks ago

Scilex Holding Company Has Appealed Lower Court Decision to the U.S. Court of Appeals for the Federal Circuit in Washington, DC and Will Continue to Vigorously Pursue its Infringement Action Against Aveva

Mar 10, 2025, 9:00 AM EDT - 2 months ago

Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from January 28, 2025 to April 11, 2025

Jan 31, 2025, 9:00 AM EST - 3 months ago

Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Dividend Stock Previously Distributed by Sorrento to its Stockholders as a Dividend to April 14, 2025

Jan 21, 2025, 11:49 AM EST - 4 months ago

Scilex Holding Company Announces that It Regains Nasdaq Compliance Under Listing Rule 5250(c)(1)

Jan 21, 2025, 9:46 AM EST - 4 months ago

Scilex Holding Company Announces Extension of the Maturity Date of its Secured Promissory Note Issued to Oramed Pharmaceuticals Inc. to December 31, 2025

Jan 21, 2025, 9:00 AM EST - 4 months ago

Scilex Holding Company Announces that Its Note Holders Intend to Participate in the Funding and Licensing of Gloperba® Ex-U.S. Commercialization Rights from Romeg Therapeutics, LLC

Jan 21, 2025, 6:00 AM EST - 4 months ago

Scilex Holding Company Announces Filing of its Quarterly Report on Form 10-Q for the Quarter Ended September 30, 2024

Jan 16, 2025, 3:38 PM EST - 4 months ago

Scilex Holding Company Amends its License Agreement with Romeg Therapeutics, LLC, For the Worldwide Rights to Commercialize Gloperba®, an FDA-Approved Prophylactic Treatment for Painful Gout Flares in Adults

Dec 30, 2024, 9:00 AM EST - 4 months ago

Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from November 7, 2024 to January 28, 2025

Dec 13, 2024, 12:23 PM EST - 5 months ago

Scilex Holding Company Announces Closing of $17 Million Registered Direct Offering

Dec 12, 2024, 8:21 AM EST - 5 months ago

Scilex Holding Company Announces $17 Million Registered Direct Offering

Dec 11, 2024, 12:49 PM EST - 5 months ago

Scilex Bio, a Controlling Interest of Joint Venture by Scilex Holding Company, Reports KDS2010 a Novel Oral Tablet Phase 2 Trial for Alzheimer's Disease (AD) Currently Enrolling with U.S. Patient Cohort to be Added in 2025

Dec 11, 2024, 7:30 AM EST - 5 months ago

Scilex Bio, a Controlling Interest of Joint Venture by Scilex Holding Company, Reports Phase 2 Trial for Obesity Currently Enrolling with U.S. Patient Cohort to be Added in 2025. Scilex Bio Reports Positive Results from the Recently Completed Phase 1 Trials Conducted by NeuroBiogen for KDS2010, a Novel Oral Tablet Recently Synthesized Potent, Selective, and Reversible Monoamine Oxidase B inhibitor

Nov 22, 2024, 6:00 AM EST - 6 months ago

Scilex Holding Company Announces Receipt of Notice from Nasdaq

Nov 6, 2024, 12:24 PM EST - 6 months ago

Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, Announces Today the Filing of a Registration Statement on Form S-4 by Denali Capital Acquisition Corp. with the Securities and Exchange Commission Relating to the Previously Announced Proposed Business Combination Between Semnur and Denali

Oct 30, 2024, 6:00 AM EDT - 7 months ago

Scilex Pharmaceuticals Inc, a Wholly Owned Subsidiary of Scilex Holding Company, Announces Successful End of Phase II Meeting with FDA Leading to an Agreed Path Forward to NDA Upon Completion of Phase III Trials for Blockbuster Product Candidate, SP-103 (Lidocaine Topical System) 5.4%, a Next-Generation, Triple-Strength Formulation of ZTlido, for the Treatment of Chronic Neck Pain Associated with Muscle Spasms

Oct 29, 2024, 6:00 AM EDT - 7 months ago

Scilex Holding Company, Following its Prior Announcement of the Record Date for a Dividend of Preferred Stock, Reiterates Information Previously Provided to Scilex Stockholders Regarding Manipulative and Naked Short Selling of Scilex Common Stock

Oct 28, 2024, 6:00 AM EDT - 7 months ago

Scilex Holding Company sets November 7, 2024 as the Record Date for a Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary

Oct 16, 2024, 4:00 AM EDT - 7 months ago

Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, Provides Timing to File in October 2024 a Registration Statement on Form S-4 with the SEC relating to the Previously Announced Proposed Business Combination Between Semnur and Denali with a Pre-Transaction Equity Value of $2.5 Billion

Oct 8, 2024, 1:58 PM EDT - 7 months ago

Scilex Holding Company Provides Certain Preliminary Unaudited Financial Results for the Quarter Ended September 30, 2024

Oct 8, 2024, 11:50 AM EDT - 7 months ago

Scilex Holding Company Announces Closing of a $50 Million Registered Convertible Financing

Oct 7, 2024, 10:00 AM EDT - 7 months ago

Oramed Pharmaceuticals Announces Restructuring of Scilex Holding Company Debt

ORMP

Oct 7, 2024, 9:52 AM EDT - 7 months ago

Scilex Holding Company Announces Signing of a $50 Million Registered Convertible Financing to Refinance and Restructure Existing Debt & Further Strengthens Financial Profile

Sep 10, 2024, 7:27 AM EDT - 8 months ago

Top 3 Health Care Stocks That Could Blast Off In September

AMN PDCO

Sep 3, 2024, 9:00 AM EDT - 9 months ago

Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, and Denali Capital Acquisition Corp. (Nasdaq: DECA) Announce Signing of a Merger Agreement for a proposed Business Combination, Providing for a Pre-Transaction Equity Value of Semnur of $2.5 Billion

Aug 30, 2024, 9:00 AM EDT - 9 months ago

Scilex Holding Company to Present Oral, Poster Presentations and Symposia on ZTlido (lidocaine topical system) at the 2024 Annual PAINWeek Conference in Las Vegas, NV on September 3-5, 2024

Aug 29, 2024, 9:00 AM EDT - 9 months ago

Scilex Holding Company Announces FDA Final Approval to Precision Dosing for GLOPERBA® Label

Aug 21, 2024, 9:00 AM EDT - 9 months ago

Scilex Holding Company Announces the U.S. Patent and Trademark Office Will Be Issuing New ELYXYB® Patent Related to the Treatment of Acute Pain

Aug 9, 2024, 9:00 AM EDT - 9 months ago

Scilex Holding Company Enters into Master Distributor Agreement Among CH Trading Group and Devart Middle East for the Distribution of ZTlido® in Morocco, Tunisia, Libya, Jordan, Iraq, and South Africa

Jul 24, 2024, 10:52 AM EDT - 10 months ago

Scilex Holding Company Announces Publication of Its Inaugural Sustainability Report

Jul 3, 2024, 10:51 AM EDT - 11 months ago

Non-Opioid Pain Therapy-Focused Semnur Pharmaceuticals Strikes $2B SPAC Deal For NASDAQ Debut

Jul 2, 2024, 6:24 PM EDT - 11 months ago

Semnur Pharmaceuticals to go public in SPAC deal of up to $2 billion with Denali Capital

Jul 2, 2024, 5:15 PM EDT - 11 months ago

Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, and Denali Capital Acquisition Corp. (Nasdaq: DECA) Enter into a Letter of Intent for a Proposed Business Combination

Jul 2, 2024, 9:00 AM EDT - 11 months ago

Scilex Holding Company to Ring Nasdaq Closing Bell on Friday, July 5th at 4:00PM ET at the Nasdaq MarketSite in Times Square, New York

Jun 20, 2024, 9:00 AM EDT - 11 months ago

Scilex Holding Company Partners with New National Distributor, Endeavor Distribution LLC.

Jun 14, 2024, 1:41 PM EDT - 11 months ago

Scilex Holding Company Announces Publication in PAIN Journal Regarding Phase 3 Results of the Pivotal Registration Trial of SP-102 (SEMDEXA™) in Lumbosacral Radicular Pain (Sciatica)

Jun 11, 2024, 7:20 PM EDT - 1 year ago

Scilex Holding Company Announces 5-Year Term of $100 Million Financing with Royalty-Based Payments and Potential Strategic Transactions with Perigrove and its Portfolio Companies

Jun 11, 2024, 9:00 AM EDT - 1 year ago

Scilex Holding Company Announces That Many National Pharmacy Chains and Independent Pharmacies Have Begun Stocking GLOPERBA®

Jun 10, 2024, 11:49 AM EDT - 1 year ago

Scilex Holding Company Announces Stocking of GLOPERBA® is Underway in all of the Wholesalers with which Scilex has Stocking Arrangements Throughout the U.S.

Jun 6, 2024, 2:56 PM EDT - 1 year ago

Scilex Holding Company announces the U.S. FDA has approved the sNDA for commercial manufacturing of Gloperba® which will be launched in the US in the week of June 10th 2024

May 30, 2024, 1:19 PM EDT - 1 year ago

Scilex Holding Company Sends Letters to the U.S. Securities and Exchange Commission and Financial Industry Regulatory Authority Regarding Illegal Market Manipulation of the Common Stock of Scilex Holding Company

May 24, 2024, 1:40 PM EDT - 1 year ago

Scilex Holding Company Announces it has been Added to the MSCI Global Microcap Index

May 24, 2024, 9:00 AM EDT - 1 year ago

Scilex Holding Company Sends Letter to U.S. House of Representatives on Illegal Market Manipulation of the Common Stock of Scilex Holding Company

May 14, 2024, 9:00 AM EDT - 1 year ago

Scilex Holding Company Announces Final Court Approval of a Settlement Agreement with Takeda Pharmaceuticals to Resolve the Paragraph IV Patent Infringement Lawsuit Relating to Scilex's intent to Expand the Label for its FDA-Approved Liquid Colchicine Prod